These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22234095)

  • 21. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients.
    Prayson RA; Goldblum JR; Hart WR
    Am J Surg Pathol; 1997 Apr; 21(4):383-91. PubMed ID: 9130984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters.
    Gupta M; Laury AL; Nucci MR; Quade BJ
    Histopathology; 2018 Aug; 73(2):284-298. PubMed ID: 29537683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelioid Leiomyosarcoma of the Uterus: Modern Outcome-based Appraisal of Diagnostic Criteria in a Large Institutional Series.
    Chapel DB; Nucci MR; Quade BJ; Parra-Herran C
    Am J Surg Pathol; 2022 Apr; 46(4):464-475. PubMed ID: 34419987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stanford parameters stratify the risk of recurrence in gynecologic smooth muscle tumors of uncertain malignant potential.
    Travaglino A; Raffone A; Gencarelli A; Caldarelli C; Granata M; Santoro A; Zannoni GF; Mollo A; Zullo F; Insabato L
    APMIS; 2021 Jun; 129(6):283-290. PubMed ID: 33786917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
    Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
    J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
    Quade BJ
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined uterine smooth muscle tumour: a challenging case.
    Viola P; Colasante A
    Pathologica; 2012 Aug; 104(4):193-7. PubMed ID: 23316624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases.
    Croce S; Young RH; Oliva E
    Am J Surg Pathol; 2014 Oct; 38(10):1330-9. PubMed ID: 25140893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological characteristics and clinical outcome of uterine leiomyomas associated with pregnancy.
    Muezzinoglu B; Corakci A
    Pathol Res Pract; 2011 Nov; 207(11):691-4. PubMed ID: 21993296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ["STUMP" (smooth muscle tumour of uncertain malignant potential), a tumour of the uterus in pregnancy--a diagnostic and therapeutic challenge].
    Clauss S; Höller S; Hegi L; Blum R; Hösli I
    Z Geburtshilfe Neonatol; 2010 Apr; 214(2):74-7. PubMed ID: 20411475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Border-line smooth-muscle tumor of the uterus: analysis of 131 patients].
    Ma SK; Zhang HT; Wu LY; Liu LY; Li B
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):698-700. PubMed ID: 16438896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mesenchymal uterine tumors. Leiomyomas].
    Lax S
    Pathologe; 2009 Jul; 30(4):274-83. PubMed ID: 19495761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma".
    Kraft S; Fletcher CD
    Am J Surg Pathol; 2011 Apr; 35(4):599-607. PubMed ID: 21358302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma.
    Martin SA; Sears DL; Sebo TJ; Lohse CM; Cheville JC
    Am J Surg Pathol; 2002 Mar; 26(3):292-300. PubMed ID: 11859200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
    Atkins KA; Arronte N; Darus CJ; Rice LW
    Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior.
    Hornick JL; Fletcher CD
    Am J Surg Pathol; 2011 Feb; 35(2):190-201. PubMed ID: 21263239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.